He Qiheng, Li Tianfei, Xiong Ying, Xia Xiaoyu, Dang Yuanyuan, Chen Xueling, Geng Xiaoli, He Jianghong, Yang Yi, Zhao Jizong
Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Department of Neurosurgery, China National Clinical Research Center for Neurological Diseases, Beijing, China.
Front Aging Neurosci. 2022 Nov 3;14:1032740. doi: 10.3389/fnagi.2022.1032740. eCollection 2022.
Spinal cord stimulation (SCS) is a promising treatment for patients with disorders of consciousness (DoC); however, the laboratory examinations and different electrodes (permanent #39286 vs. temporary percutaneous #3777, Medtronic, USA) that are associated with postoperative outcomes are unclear. The study aims to study the association between the change in postoperative cerebrospinal fluid (CSF) protein level and improvement in consciousness after SCS in DoC patients and to explore whether different electrodes were associated with elevated CSF protein levels.
A total of 66 DoC patients who received SCS treatment from December 2019 to December 2021 were retrospectively analyzed. Patients were grouped according to their elevated CSF protein level. The clinical characteristics of the patients and SCS stimulation parameters were compared. The preoperative sagittal diameter of the spinal canal is the distance from the midpoint of the posterior border of the vertebral body to the midpoint of the posterior wall of the spinal canal at the level of the superior border of C3. The postoperative sagittal diameter of the spinal canal is the distance from the midpoint of the posterior edge of the vertebral body to the anterior edge of the stimulation electrode. Patients with improved postoperative CRS-R scores greater than 3 or who progressed to the MCS + /eMCS were classified as the improved group and otherwise regarded as poor outcome.
We found that more DoC patients had elevated CSF protein levels among those receiving SCS treatment with permanent electrodes than temporary percutaneous electrodes ( = 0.001), and elevated CSF protein levels were significantly associated with a reduced sagittal diameter ( = 0.044). In DoC patients receiving SCS treatment, we found that elevated CSF protein levels ( = 0.022) and preoperative diagnosis ( = 0.003) were significantly associated with poor outcomes at 3 months. Logistic regression analysis showed that elevated CSF protein levels were significantly associated with poor outcomes (OR 1.008, 95% CI 1.001-1.016, = 0.032).
The results suggest that reducing the effect of electrode pads on anatomical changes may help improve the outcomes of DoC patients receiving SCS treatment. CSF protein levels are associated with poor postoperative outcomes and whether they are potential biomarkers in DoC patients receiving SCS treatment remain further exploration.
脊髓刺激(SCS)是意识障碍(DoC)患者一种有前景的治疗方法;然而,与术后结果相关的实验室检查和不同电极(美敦力公司美国产的永久性#39286电极与临时性经皮#3777电极)尚不清楚。本研究旨在探讨意识障碍患者接受脊髓刺激治疗后脑脊液(CSF)蛋白水平变化与意识改善之间的关联,并探究不同电极是否与脑脊液蛋白水平升高有关。
回顾性分析2019年12月至2021年12月期间接受脊髓刺激治疗的66例意识障碍患者。根据脑脊液蛋白水平升高情况对患者进行分组。比较患者的临床特征和脊髓刺激参数。术前椎管矢状径是指椎体后缘中点至C3上缘水平椎管后壁中点的距离。术后椎管矢状径是指椎体后缘中点至刺激电极前缘的距离。术后CRS-R评分提高大于3分或进展至MCS + /eMCS的患者被分类为改善组,否则视为预后不良。
我们发现,接受永久性电极脊髓刺激治疗的意识障碍患者中脑脊液蛋白水平升高的患者比接受临时性经皮电极治疗的患者更多(P = 0.001),脑脊液蛋白水平升高与矢状径减小显著相关(P = 0.044)。在接受脊髓刺激治疗的意识障碍患者中,我们发现脑脊液蛋白水平升高(P = 0.022)和术前诊断(P = 0.003)与3个月时的不良预后显著相关。逻辑回归分析表明,脑脊液蛋白水平升高与不良预后显著相关(OR 1.008,95%CI 1.001 - 1.016,P = 0.032)。
结果表明,减少电极垫对解剖结构变化的影响可能有助于改善接受脊髓刺激治疗的意识障碍患者的预后。脑脊液蛋白水平与术后不良预后相关,其是否为接受脊髓刺激治疗的意识障碍患者的潜在生物标志物仍有待进一步探索。